RhAPPcast

Rheumatology Advanced Practice Providers (RhAPP)
  • 5.0 (5)
  • Medicine

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

  1. 6h ago

    RhAPPcast: EULAR PsA RhAPP UP: Part 1

    In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Audrey Gibson, PA-C, as they kick off the first episode of a special three-part RhAPP Up series focused on key psoriatic arthritis updates from the 2026 EULAR Congress. They discuss several key abstracts from the meeting, including a head-to-head trial comparing two different therapeutic approaches in active psoriatic arthritis and what the results may mean for treatment decisions in clinical practice. The conversation highlights how new data may help guide therapy selection and improve patient care. The episode also reviews emerging data on a novel IL-17A inhibitor and its impact on patient-reported outcomes, including pain, fatigue, physical function, and quality of life. The conversation emphasizes the importance of aligning treatment goals with what matters most to patients, not just traditional clinical endpoints. Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode offers practical insights into evolving psoriatic arthritis treatment strategies, emerging biologic therapies, and the growing emphasis on precision medicine in inflammatory arthritis care. Stay tuned for Part 2 of the RhAPP Up series and visit the Content Rheum to stay up to date with the latest clinical insights in rheumatologic care.

    17 min

  2. 2d ago

    RhAPPcast: EULAR ILD RhAPP Up: Part 3

    In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, and guest Jessica Glennie, CNP, conclude their 2026 EULAR ILD RhAPP Up Series with a review of important new research on rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and progressive pulmonary fibrosis (PPF). The discussion examines long-term data showing that interstitial lung disease can develop in patients with rheumatoid arthritis despite effective disease control, reinforcing the importance of ongoing screening and pulmonary monitoring. The episode also highlights new findings on an emerging antifibrotic therapy, including its potential to slow lung function decline, reduce respiratory complications, and improve outcomes for patients with autoimmune-related lung disease. Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode offers practical insights into identifying patients at risk for ILD, the value of early detection, and advances in the treatment of progressive pulmonary fibrosis. Stay tuned for new episodes highlighting the Osteoporosis and PsA Abstracts from EULAR 2026. Visit the Content Rheum and RhAPP ACE app for more rheumatology education.

    20 min

  3. 6d ago

    RhAPPcast: EULAR ILD RhAPP Up: Part 2

    In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, welcomes Jessica Glennie, CNP, to continue their 2026 EULAR ILD RhAPP Up series by reviewing the latest research on systemic sclerosis-associated interstitial lung disease (SSc-ILD) and progressive pulmonary fibrosis (PPF). The discussion highlights new real-world data showing that many patients with early SSc-ILD maintain stable lung function when closely monitored and treated appropriately. The episode also explores the safety and tolerability of an emerging antifibrotic therapy, reviewing its potential role in slowing disease progression while offering a favorable side effect profile for patients with autoimmune-related lung disease. Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode delivers practical insights into early disease monitoring, evolving treatment options, and strategies to help improve long-term outcomes for patients with ILD. Stay tuned for Part 3 and visit the Content Rheum to stay up to date with the latest clinical insights in rheumatologic care.

    14 min

  4. Jun 16

    RhAPPcast: EULAR ILD RhAPP UP: Part 1

    In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Jessica Glennie, CNP, as they discuss key interstitial lung disease (ILD) updates from the 2026 EULAR Congress in the first episode of a special three-part RhAPP Up series. They explore the healthcare and financial impact of connective tissue disease-associated ILD (CTD-ILD), highlighting why early diagnosis and treatment are so important for improving patient outcomes and reducing long-term costs. The episode also reviews emerging research on a potential new therapy for systemic sclerosis that may target multiple aspects of the disease and help slow its progression. Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode provides practical insights into the latest ILD research, evolving treatment strategies, and the value of early, multidisciplinary care. Stay tuned for Part 2 and visit the Content Rheum to stay up to date with the latest clinical insights in rheumatologic care.

    20 min

  5. Jun 11

    RhAPPcast: TYK2 Inhibition in PsA, Sjögren’s and SLE: What APPs Need to Know as Future Uses Emerge

    Stay ahead of the latest advancements in rheumatology with this in-depth RhAPPcast episode exploring TYK2 inhibition and its expanding role in immune-mediated diseases. Hosted by Amanda Mixon, PA-C, this episode features expert insights from Danielle Gatti-Palumbo, PharmD, and Jennifer Mylod, DNP, as they break down the science behind TYK2 signaling within the JAK-STAT pathway and its clinical relevance in conditions like psoriatic arthritis, systemic lupus erythematosus (SLE), and Sjögren’s syndrome. Learn how TYK2 inhibitors—such as deucravacitinib—are reshaping treatment strategies by targeting key cytokines like IL-12, IL-23, and type 1 interferons, offering a potentially effective oral alternative with a differentiated safety profile compared to traditional JAK inhibitors. The discussion highlights pivotal clinical trials including POETYK PSO-1, POETYK PSO-2, and emerging phase 3 data in psoriatic arthritis, as well as promising findings from the PAISLEY trial in lupus. Additionally, the episode explores the unmet need in Sjögren’s syndrome and how evolving trial designs and outcome measures may pave the way for future targeted therapies. Whether you're a rheumatology provider, advanced practice provider (APP), or healthcare professional interested in autoimmune disease management, this episode delivers key clinical insights, trial data, and future considerations shaping the next wave of immunomodulatory therapies. For more rheumatology education, check out the RhAPP Content Rheum or download the RhAPP ACE app.

    20 min

  6. Jun 9

    Journal Club Review: SURMOUNT-5

    Explore the latest evidence in obesity management in this journal club review of the SURMOUNT-5 clinical trial, presented by Bharati Bhardwaja, PharmD, from Kaiser Permanente Colorado. This video breaks down a Phase 3b randomized trial comparing tirzepatide and semaglutide in adults with obesity without type 2 diabetes, highlighting key efficacy and safety outcomes over 72 weeks. Learn how tirzepatide demonstrated superior weight loss compared to semaglutide, achieving an average 20.2% reduction in body weight versus 13.7%, along with significantly greater reductions in waist circumference. The discussion also reviews clinically meaningful weight loss thresholds, showing that more patients on tirzepatide achieved ≥10%, ≥15%, ≥20%, and even ≥30% weight reduction. Safety findings are also covered, including common gastrointestinal side effects such as nausea, diarrhea, constipation, and vomiting, as well as considerations during dose escalation. Designed for healthcare professionals and clinicians managing obesity and metabolic disease, this video provides a clear, evidence-based comparison of two leading therapies, offering practical insights to guide treatment decisions and optimize patient outcomes in obesity care. For more expert-led education, visit the Content Rheum and stay up to date with the latest clinical insights in rheumatologic care.

    4 min

  7. Jun 4

    Medication Review: Deucravacitinib Dosing, Administration, DDIs, & Safety in Clinical Practice

    In this educational Medication Review, Claudia Rivera-Salas, DNP, provides a practical overview of deucravacitinib and its role in the treatment of immune-mediated diseases such as psoriatic arthritis and plaque psoriasis. This video highlights why deucravacitinib, a selective TYK2 inhibitor, is gaining attention for its unique mechanism of action and ease of use in clinical practice. Learn how deucravacitinib stands out as a once-daily oral therapy with a fixed dose—requiring no titration, no routine dose adjustments, and the flexibility to be taken with or without food, helping to support patient adherence. Claudia explains how its targeted inhibition of the TYK2 regulatory domain differentiates it from traditional JAK inhibitors, contributing to a favorable safety profile without boxed warnings for major adverse cardiovascular events (MACE), venous thromboembolism (VTE), malignancy, or serious infections observed in clinical trials. The discussion also covers key clinical considerations, including minimal drug-drug interactions, the lack of required routine lab monitoring, and important precautions for patients with severe hepatic impairment or those who are pregnant or breastfeeding. Currently approved for adults with moderate to severe plaque psoriasis and psoriatic arthritis, deucravacitinib is also being investigated across a range of autoimmune conditions. Watch this video to understand how deucravacitinib fits into modern rheumatology and dermatology treatment strategies, and why its balance of efficacy, safety, and convenience makes it a valuable option for both providers and patients managing chronic inflammatory diseases. For more rheumatology resources, visit the RhAPP Content Rheum, RhAPP ACE app, or follow RhAPP on Instagram, LinkedIn, or Facebook.

    2 min

  8. Jun 2

    Podcast: Weight, Wellness, and PsA: Empowering Conversations & Action in the Rheumatology Clinic

    Discover how obesity impacts outcomes in psoriatic arthritis in this insightful episode featuring expert perspectives from rheumatology clinicians, Amanda Mixon, PA-C and Jeannette Hart, PA-C. This discussion explores the growing recognition of obesity as a chronic, pro-inflammatory condition that not only worsens joint symptoms and physical function but also reduces treatment response in patients with psoriatic arthritis. Learn practical, real-world strategies for integrating weight assessment into routine rheumatology care, including how to approach sensitive conversations with patients in a stigma-free, supportive way. The episode highlights how even modest weight loss (5–10%) can improve disease activity, reduce inflammation, and enhance overall health outcomes. Clinicians will also gain insights into building obesity-focused care pathways within their practice, from lifestyle counseling and patient education to incorporating emerging pharmacologic options like GLP-1 therapies. Designed for healthcare professionals, this episode emphasizes the importance of empathy, patient partnership, and science-driven communication when addressing weight management in psoriatic arthritis. Whether you’re looking to improve patient engagement, optimize treatment response, or expand your approach to comprehensive inflammatory disease care, this conversation offers actionable guidance to elevate your clinical practice. For more expert-led education, visit the Content Rheum and stay up to date with the latest clinical insights in rheumatologic care.

    18 min
See All (195)

Ratings & Reviews

5
out of 5
5 Ratings

About

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

Information

  • Creator
    Rheumatology Advanced Practice Providers (RhAPP)
  • Years Active
    2023 - 2026
  • Episodes
    195
  • Rating
    Clean
  • Copyright
    © 2025 RhAPPcast
  • Show Website
    RhAPPcast

You Might Also Like